Bermuda

Country

  • Myovant CEO Says Buoyant IPO Reflects High Interest In Women's Health

     
    • By 

    Recently created biotech Myovant has floated on the New York Stock Exchange to raise capital to progress its two lead candidate therapies; one for women's health conditions and another for prostate, and says Pfizer's sizable stake in the IPO reflects rising interest in these therapy areas.

ADVERTISEMENT